EsoCap AG

Our vision is to enhance the lives of patients affected by esophageal diseases by pioneering innovative treatments tailored to the unique challenges of the esophagus.

Unlike other parts of the digestive tract, the esophagus presents a significant challenge for drug delivery—swallowed medications pass through in mere seconds, limiting their effectiveness.

We are committed to overcoming this barrier with solutions designed to improve treatment outcomes and patient well-being.

Featured News

Milestones

ACESO Phase II Study

EsoCap has successfully completed the ACESO double-blind, randomised, placebo-controlled Phase II study in patients with eosinophilic esophagitis (EoE), a chronic inflammatory disease. The advanced drug delivery technology ensures that therapeutic agents are precisely targeted to the esophagus, allowing for significantly longer contact time with the drug, thereby enhancing treatment efficacy and improving patient outcomes.

The data from the ACESO study has been published in the Journal Alimentary Pharmacology and Therapeutics.

Learn more about our clinical development

Revolutionizing Esophageal Drug Delivery

EsoCap has successfully integrated small molecules, peptides, an antibody and liposomal encapsulated RNA into its innovative film technology, paving the way for new applications, particularly in the treatment of reflux disease, esophageal cancer, Barrett’s disease and other related gastrointestinal diseases.

The lead candidate ESO-101 has received Orphan Drug Designation from the US Food & Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).

Explore EsoCap's Scientific Platform

What is EsoCap?

Updates

News

05 June 2026
Professor Werner Weitschies Receives the 2026 Pearls of Bioequivalence and Biopharmaceutics Award for Groundbreaking Esophageal Drug Delivery Innovation
Read More
01 October 2025
University of Greifswald Pioneers 3D-Printed Mucoadhesive Films for Individualized Esophageal Drug Delivery
Read More
22 April 2025
EsoCap to Present Key Phase II Results on Novel Drug Delivery System in Eosinophilic Esophagitis at DDW 2025
Read More
17 December 2024
EsoCap announces publication of comprehensive Phase II results demonstrating ESO-101’s effectiveness in eosinophilic esophagitis
Read More
11 October 2024
EsoCap Announces ACESO Phase II Data Presentation at UEG Week 2024
Read More
28 August 2024
EsoCap Announces Publication “Scalability of API-Loaded Multifilament Yarn Production by Hot-Melt Extrusion and Evaluation of Fiber-Based Dosage Forms”
Read More
20 August 2024
EsoCap announces publication of “Modification of the Biorelevant Release Testing of Esophageal Applied Mucoadhesive Films and Development of Formulation Strategies to Increase the Mucosal Contact Time“
Read More
27 June 2024
EsoCap announces publication of “Stability of Free and Liposomal Encapsulated RNA on a Mucoadhesive PVA Polymer for Esophageal RNA Drug Targeting Using the EsoCap System”
Read More
20 June 2024
EsoCap AG sinker development featured in Fette Compacting's customer magazine "What's Next"
Read More
29 November 2023
Most cited – Greifswald scientist & EsoCap co-founder tops the list of 'Highly Cited Researchers'
Read More
Newsflow

“The EsoCap novel smart drug delivery technology will enable long-lasting local therapy of the esophagus for the first time. The positive outcome of the ACESO Phase II study with ESO-101 in patients with eosinophilic esophagitis (EoE) and the publication in a peer-reviewed journal are an important validation of our targeted, topical delivery platform, which has been designed to increase mucosal contact time and drug deposition in the esophagus. This marks an important milestone for EsoCap in advancing treatment options for patients with eosinophilic esophagitis.”

Isabelle Racamier

CEO

Contact

EsoCap AG

Malzgasse 9, CH-4052 Basel